US OptionsDetailed Quotes
CTXR250516P1500
- 0.75
- -0.05-6.25%
15min DelayClose May 6 16:00 ET
0.75High0.75Low
0.75Open0.80Pre Close1 Volume101 Open Interest1.50Strike Price75.00Turnover759.83%IV-3.16%PremiumMay 16, 2025Expiry Date0.77Intrinsic Value100Multiplier10DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.4840Delta0.4411Gamma0.75Leverage Ratio-0.0188Theta-0.0003Rho-0.36Eff Leverage0.0005Vega
Citius Pharmaceuticals Stock Discussion
Citius Secures Strategic $2M Funding to Accelerate LYMPHIR Launch - Key Details Revealed
👀
1. NFA (Not Financial Advice!) This is NOT a BUY or SELL advice.
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If y...
getting some action wonder why
Citius Pharmaceuticals Secures Critical J-Code for LYMPHIR as Cash Reserves Hit $1.1M
Medicare Breakthrough: Citius's Cancer Drug LYMPHIR Gets Crucial Insurance Code - Major Win for CTCL Patients
Citius Pharmaceuticals and Citius Oncology Announce Unique Permanent J-Code Issued for Lymphir by Centers for Medicare and Medicaid Services
Citius Pharmaceuticals Advances LYMPHIR Launch Plans for Breakthrough CTCL Treatment
No comment yet